Abstract
Summary
Sartan-series drugs are one of the commonly used clinical antihypertensive drugs, ending with "sartan", such as losartan, valsartan, telmisartan, also known as angiotensin II receptor antagonists or Angiotensin receptor blocker (ARBs). They include irbesartan, valsartan, losartan and candesartan. If the name of a medicine ends in ‘sartan’, it is an ARB.
The global Sartan-series Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of %during the forecast period.
The US & Canada market for Sartan-series Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The China market for Sartan-series Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The Europe market for Sartan-series Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key manufacturers of Sartan-series Drugs include Novartis, Merck & Co, Sanofi, Pfizer, Bayer, AstraZeneca, Daiichi Sankyo, Takeda, Bristol-Myers Squibb Company, Boehringer Ingelheim, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Sartan-series Drugs market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Sartan-series Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Sartan-series Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Sartan-series Drugs revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Sartan-series Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Sartan-series Drugs revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Novartis, Merck & Co, Sanofi, Pfizer, Bayer, AstraZeneca, Daiichi Sankyo, Takeda, Bristol-Myers Squibb Company, Boehringer Ingelheim, etc.
Market Segmentation
By Company
Novartis
Merck & Co
Sanofi
Pfizer
Bayer
AstraZeneca
Daiichi Sankyo
Takeda
Bristol-Myers Squibb Company
Boehringer Ingelheim
Abbott
Teva Pharmaceutical
Shenzhen Salubris Pharmaceuticals
Segment by Type
Losartan
Valsartan
Irbesartan
Telmisartan
Olmesartan
Candesartan
Sacubitril/valsartan
Others
Segment by Application
Hospital Pharmaty
Retail Pharmacy
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of South America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Sartan-series Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sartan-series Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sartan-series Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
The global Sartan-series Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of %during the forecast period.
The US & Canada market for Sartan-series Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The China market for Sartan-series Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The Europe market for Sartan-series Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key manufacturers of Sartan-series Drugs include Novartis, Merck & Co, Sanofi, Pfizer, Bayer, AstraZeneca, Daiichi Sankyo, Takeda, Bristol-Myers Squibb Company, Boehringer Ingelheim, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Sartan-series Drugs market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Sartan-series Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Sartan-series Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Sartan-series Drugs revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Sartan-series Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Sartan-series Drugs revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Novartis, Merck & Co, Sanofi, Pfizer, Bayer, AstraZeneca, Daiichi Sankyo, Takeda, Bristol-Myers Squibb Company, Boehringer Ingelheim, etc.
Market Segmentation
By Company
Novartis
Merck & Co
Sanofi
Pfizer
Bayer
AstraZeneca
Daiichi Sankyo
Takeda
Bristol-Myers Squibb Company
Boehringer Ingelheim
Abbott
Teva Pharmaceutical
Shenzhen Salubris Pharmaceuticals
Segment by Type
Losartan
Valsartan
Irbesartan
Telmisartan
Olmesartan
Candesartan
Sacubitril/valsartan
Others
Segment by Application
Hospital Pharmaty
Retail Pharmacy
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of South America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Sartan-series Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sartan-series Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sartan-series Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Sartan-series Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Losartan
1.2.3 Valsartan
1.2.4 Irbesartan
1.2.5 Telmisartan
1.2.6 Olmesartan
1.2.7 Candesartan
1.2.8 Sacubitril/valsartan
1.3 Market by Application
1.3.1 Global Sartan-series Drugs Market Share by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmaty
1.3.3 Retail Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Sartan-series Drugs Market Perspective (2019-2030)
2.2 Global Sartan-series Drugs Growth Trends by Region
2.2.1 Global Sartan-series Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Sartan-series Drugs Historic Market Size by Region (2019-2024)
2.2.3 Sartan-series Drugs Forecasted Market Size by Region (2025-2030)
2.3 Sartan-series Drugs Market Dynamics
2.3.1 Sartan-series Drugs Industry Trends
2.3.2 Sartan-series Drugs Market Drivers
2.3.3 Sartan-series Drugs Market Challenges
2.3.4 Sartan-series Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Sartan-series Drugs by Players
3.1.1 Global Sartan-series Drugs Revenue by Players (2019-2024)
3.1.2 Global Sartan-series Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Sartan-series Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Sartan-series Drugs, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Sartan-series Drugs Market Concentration Ratio
3.4.1 Global Sartan-series Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sartan-series Drugs Revenue in 2023
3.5 Global Key Players of Sartan-series Drugs Head office and Area Served
3.6 Global Key Players of Sartan-series Drugs, Product and Application
3.7 Global Key Players of Sartan-series Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Sartan-series Drugs Breakdown Data by Type
4.1 Global Sartan-series Drugs Historic Market Size by Type (2019-2024)
4.2 Global Sartan-series Drugs Forecasted Market Size by Type (2025-2030)
5 Sartan-series Drugs Breakdown Data by Application
5.1 Global Sartan-series Drugs Historic Market Size by Application (2019-2024)
5.2 Global Sartan-series Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Sartan-series Drugs Market Size (2019-2030)
6.2 North America Sartan-series Drugs Market Size by Type
6.2.1 North America Sartan-series Drugs Market Size by Type (2019-2024)
6.2.2 North America Sartan-series Drugs Market Size by Type (2025-2030)
6.2.3 North America Sartan-series Drugs Market Share by Type (2019-2030)
6.3 North America Sartan-series Drugs Market Size by Application
6.3.1 North America Sartan-series Drugs Market Size by Application (2019-2024)
6.3.2 North America Sartan-series Drugs Market Size by Application (2025-2030)
6.3.3 North America Sartan-series Drugs Market Share by Application (2019-2030)
6.4 North America Sartan-series Drugs Market Size by Country
6.4.1 North America Sartan-series Drugs Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Sartan-series Drugs Market Size by Country (2019-2024)
6.4.3 North America Sartan-series Drugs Market Share by Country (2025-2030)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Sartan-series Drugs Market Size (2019-2030)
7.2 Europe Sartan-series Drugs Market Size by Type
7.2.1 Europe Sartan-series Drugs Market Size by Type (2019-2024)
7.2.2 Europe Sartan-series Drugs Market Size by Type (2025-2030)
7.2.3 Europe Sartan-series Drugs Market Share by Type (2019-2030)
7.3 Europe Sartan-series Drugs Market Size by Application
7.3.1 Europe Sartan-series Drugs Market Size by Application (2019-2024)
7.3.2 Europe Sartan-series Drugs Market Size by Application (2025-2030)
7.3.3 Europe Sartan-series Drugs Market Share by Application (2019-2030)
7.4 Europe Sartan-series Drugs Market Size by Country
7.4.1 Europe Sartan-series Drugs Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Sartan-series Drugs Market Size by Country (2019-2024)
7.4.3 Europe Sartan-series Drugs Market Size by Country (2025-2030)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
7.4.9 Nordic Countries
8 China
8.1 China Sartan-series Drugs Market Size (2019-2030)
8.2 China Sartan-series Drugs Market Size by Type
8.2.1 China Sartan-series Drugs Market Size by Type (2019-2024)
8.2.2 China Sartan-series Drugs Market Size by Type (2025-2030)
8.2.3 China Sartan-series Drugs Market Share by Type (2019-2030)
8.3 China Sartan-series Drugs Market Size by Application
8.3.1 China Sartan-series Drugs Market Size by Application (2019-2024)
8.3.2 China Sartan-series Drugs Market Size by Application (2025-2030)
8.3.3 China Sartan-series Drugs Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Sartan-series Drugs Market Size (2019-2030)
9.2 Asia Sartan-series Drugs Market Size by Type
9.2.1 Asia Sartan-series Drugs Market Size by Type (2019-2024)
9.2.2 Asia Sartan-series Drugs Market Size by Type (2025-2030)
9.2.3 Asia Sartan-series Drugs Market Share by Type (2019-2030)
9.3 Asia Sartan-series Drugs Market Size by Application
9.3.1 Asia Sartan-series Drugs Market Size by Application (2019-2024)
9.3.2 Asia Sartan-series Drugs Market Size by Application (2025-2030)
9.3.3 Asia Sartan-series Drugs Market Share by Application (2019-2030)
9.4 Asia Sartan-series Drugs Market Size by Region
9.4.1 Asia Sartan-series Drugs Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Sartan-series Drugs Market Size by Region (2019-2024)
9.4.3 Asia Sartan-series Drugs Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Sartan-series Drugs Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Sartan-series Drugs Market Size by Type
10.2.1 Middle East, Africa, and Latin America Sartan-series Drugs Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Sartan-series Drugs Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Sartan-series Drugs Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Sartan-series Drugs Market Size by Application
10.3.1 Middle East, Africa, and Latin America Sartan-series Drugs Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Sartan-series Drugs Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Sartan-series Drugs Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Sartan-series Drugs Market Size by Country
10.4.1 Middle East, Africa, and Latin America Sartan-series Drugs Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Sartan-series Drugs Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Sartan-series Drugs Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Sartan-series Drugs Introduction
11.1.4 Novartis Revenue in Sartan-series Drugs Business (2019-2024)
11.1.5 Novartis Recent Development
11.2 Merck & Co
11.2.1 Merck & Co Company Details
11.2.2 Merck & Co Business Overview
11.2.3 Merck & Co Sartan-series Drugs Introduction
11.2.4 Merck & Co Revenue in Sartan-series Drugs Business (2019-2024)
11.2.5 Merck & Co Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Sartan-series Drugs Introduction
11.3.4 Sanofi Revenue in Sartan-series Drugs Business (2019-2024)
11.3.5 Sanofi Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Sartan-series Drugs Introduction
11.4.4 Pfizer Revenue in Sartan-series Drugs Business (2019-2024)
11.4.5 Pfizer Recent Development
11.5 Bayer
11.5.1 Bayer Company Details
11.5.2 Bayer Business Overview
11.5.3 Bayer Sartan-series Drugs Introduction
11.5.4 Bayer Revenue in Sartan-series Drugs Business (2019-2024)
11.5.5 Bayer Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Details
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Sartan-series Drugs Introduction
11.6.4 AstraZeneca Revenue in Sartan-series Drugs Business (2019-2024)
11.6.5 AstraZeneca Recent Development
11.7 Daiichi Sankyo
11.7.1 Daiichi Sankyo Company Details
11.7.2 Daiichi Sankyo Business Overview
11.7.3 Daiichi Sankyo Sartan-series Drugs Introduction
11.7.4 Daiichi Sankyo Revenue in Sartan-series Drugs Business (2019-2024)
11.7.5 Daiichi Sankyo Recent Development
11.8 Takeda
11.8.1 Takeda Company Details
11.8.2 Takeda Business Overview
11.8.3 Takeda Sartan-series Drugs Introduction
11.8.4 Takeda Revenue in Sartan-series Drugs Business (2019-2024)
11.8.5 Takeda Recent Development
11.9 Bristol-Myers Squibb Company
11.9.1 Bristol-Myers Squibb Company Company Details
11.9.2 Bristol-Myers Squibb Company Business Overview
11.9.3 Bristol-Myers Squibb Company Sartan-series Drugs Introduction
11.9.4 Bristol-Myers Squibb Company Revenue in Sartan-series Drugs Business (2019-2024)
11.9.5 Bristol-Myers Squibb Company Recent Development
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Details
11.10.2 Boehringer Ingelheim Business Overview
11.10.3 Boehringer Ingelheim Sartan-series Drugs Introduction
11.10.4 Boehringer Ingelheim Revenue in Sartan-series Drugs Business (2019-2024)
11.10.5 Boehringer Ingelheim Recent Development
11.11 Abbott
11.11.1 Abbott Company Details
11.11.2 Abbott Business Overview
11.11.3 Abbott Sartan-series Drugs Introduction
11.11.4 Abbott Revenue in Sartan-series Drugs Business (2019-2024)
11.11.5 Abbott Recent Development
11.12 Teva Pharmaceutical
11.12.1 Teva Pharmaceutical Company Details
11.12.2 Teva Pharmaceutical Business Overview
11.12.3 Teva Pharmaceutical Sartan-series Drugs Introduction
11.12.4 Teva Pharmaceutical Revenue in Sartan-series Drugs Business (2019-2024)
11.12.5 Teva Pharmaceutical Recent Development
11.13 Shenzhen Salubris Pharmaceuticals
11.13.1 Shenzhen Salubris Pharmaceuticals Company Details
11.13.2 Shenzhen Salubris Pharmaceuticals Business Overview
11.13.3 Shenzhen Salubris Pharmaceuticals Sartan-series Drugs Introduction
11.13.4 Shenzhen Salubris Pharmaceuticals Revenue in Sartan-series Drugs Business (2019-2024)
11.13.5 Shenzhen Salubris Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
- 13.1.1.1 Research Programs/Design
- 13.1.1.2 Market Size Estimation
- 13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
- 13.1.2.1 Secondary Sources
- 13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer